PARP-1 and PARP-2: New players in tumour development.

Role of poly(ADP-ribose) polymerase-1 in the removal of UV-induced DNA lesions by nucleotide excision repair. Proc Natl Acad Sci U S A (2013) 1.32

p53 regulates a non-apoptotic death induced by ROS. Cell Death Differ (2013) 1.25

Distinct spatiotemporal patterns and PARP dependence of XRCC1 recruitment to single-strand break and base excision repair. Nucleic Acids Res (2013) 1.00

Resistance to PARP-Inhibitors in Cancer Therapy. Front Pharmacol (2013) 0.99

Automodification switches PARP-1 function from chromatin architectural protein to histone chaperone. Proc Natl Acad Sci U S A (2014) 0.94

Not All Next Generation Sequencing Diagnostics are Created Equal: Understanding the Nuances of Solid Tumor Assay Design for Somatic Mutation Detection. Cancers (Basel) (2015) 0.94

PARP-1 regulates resistance of pancreatic cancer to TRAIL therapy. Clin Cancer Res (2013) 0.93

Chromatin dynamics in DNA double-strand break repair. Biochim Biophys Acta (2012) 0.93

Regulation of E2F1-induced apoptosis by poly(ADP-ribosyl)ation. Cell Death Differ (2014) 0.92

The PARP3- and ATM-dependent phosphorylation of APLF facilitates DNA double-strand break repair. Nucleic Acids Res (2013) 0.89

Environmentally Relevant Concentrations of Arsenite Induce Dose-Dependent Differential Genotoxicity Through Poly(ADP-Ribose) Polymerase Inhibition and Oxidative Stress in Mouse Thymus Cells. Toxicol Sci (2015) 0.85

Metabolic modulation of chromatin: implications for DNA repair and genomic integrity. Front Genet (2013) 0.85

Inherited variation in the PARP1 gene and survival from melanoma. Int J Cancer (2014) 0.85

DNA repair targeted therapy: The past or future of cancer treatment? Pharmacol Ther (2016) 0.84

PARP-2 sustains erythropoiesis in mice by limiting replicative stress in erythroid progenitors. Cell Death Differ (2014) 0.83

ARHGAP10, downregulated in ovarian cancer, suppresses tumorigenicity of ovarian cancer cells. Cell Death Dis (2016) 0.80

Fine-tuning of Smad protein function by poly(ADP-ribose) polymerases and poly(ADP-ribose) glycohydrolase during transforming growth factor β signaling. PLoS One (2014) 0.79

XI-006 induces potent p53-independent apoptosis in Ewing sarcoma. Sci Rep (2015) 0.78

Enhancing tumor-targeting monoclonal antibodies therapy by PARP inhibitors. Oncoimmunology (2015) 0.78

Automated analysis of immunohistochemistry images identifies candidate location biomarkers for cancers. Proc Natl Acad Sci U S A (2014) 0.78

YY1-binding sites provide central switch functions in the PARP-1 gene expression network. PLoS One (2012) 0.77

Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in Fanconi Anemia Head and Neck Cancers. Clin Cancer Res (2015) 0.76

FASN regulates cellular response to genotoxic treatments by increasing PARP-1 expression and DNA repair activity via NF-κB and SP1. Proc Natl Acad Sci U S A (2016) 0.76

Disruption of PARP1 function inhibits base excision repair of a sub-set of DNA lesions. Nucleic Acids Res (2015) 0.75

PARP-1/PARP-2 double deficiency in mouse T cells results in faulty immune responses and T lymphomas. Sci Rep (2017) 0.75

4-Thiazolidinone derivative Les-3833 effectively inhibits viability of human melanoma cells through activating apoptotic mechanisms. Croat Med J (2017) 0.75

ATM/MAPK7 crosstalk in cancer. Oncotarget (2017) 0.75

Cloning and characterization of the human SH3BP2 promoter. Biochem Biophys Res Commun (2012) 0.75

Free energy calculation provides insight into the action mechanism of selective PARP-1 inhibitor. J Mol Model (2016) 0.75

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 26.32

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 24.75

Genetic instabilities in human cancers. Nature (1998) 22.76

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature (2005) 19.13

The DNA-damage response in human biology and disease. Nature (2009) 17.86

Mammalian telomeres end in a large duplex loop. Cell (1999) 12.12

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet (2010) 9.72

Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol (2006) 9.58

The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer (2005) 8.99

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet (2010) 8.41

PARP inhibition: PARP1 and beyond. Nat Rev Cancer (2010) 6.70

DNA repair pathways as targets for cancer therapy. Nat Rev Cancer (2008) 6.69

The PARP superfamily. Bioessays (2004) 6.14

IgH class switching and translocations use a robust non-classical end-joining pathway. Nature (2007) 6.05

MMEJ repair of double-strand breaks (director's cut): deleted sequences and alternative endings. Trends Genet (2008) 6.00

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature (2008) 5.98

Histones: annotating chromatin. Annu Rev Genet (2009) 5.93

Resistance to therapy caused by intragenic deletion in BRCA2. Nature (2008) 5.85

Aberrant rel/nfkb genes and activity in human cancer. Oncogene (1999) 5.62

DNA processing is not required for ATM-mediated telomere damage response after TRF2 deletion. Nat Cell Biol (2005) 5.49

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med (2009) 4.68

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A (2008) 4.61

Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol (2009) 4.14

Chromosome nondisjunction yields tetraploid rather than aneuploid cells in human cell lines. Nature (2005) 4.06

PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res (2006) 4.06

Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J Biol Chem (2002) 3.92

A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic Acids Res (2003) 3.85

(ADP-ribose)n participates in DNA excision repair. Nature (1980) 3.76

Poly(ADP-ribose)-dependent regulation of DNA repair by the chromatin remodeling enzyme ALC1. Science (2009) 3.68

Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining. J Biol Chem (2004) 3.64

The emerging role of nuclear architecture in DNA repair and genome maintenance. Nat Rev Mol Cell Biol (2009) 3.50

Reciprocal binding of PARP-1 and histone H1 at promoters specifies transcriptional outcomes. Science (2008) 3.45

Toward a unified nomenclature for mammalian ADP-ribosyltransferases. Trends Biochem Sci (2010) 3.32

A chromatin localization screen reveals poly (ADP ribose)-regulated recruitment of the repressive polycomb and NuRD complexes to sites of DNA damage. Proc Natl Acad Sci U S A (2010) 3.31

Transcriptional control by PARP-1: chromatin modulation, enhancer-binding, coregulation, and insulation. Curr Opin Cell Biol (2008) 3.18

Spontaneous homologous recombination is induced by collapsed replication forks that are caused by endogenous DNA single-strand breaks. Mol Cell Biol (2005) 3.10

Poly(ADP-ribosyl)ation directs recruitment and activation of an ATP-dependent chromatin remodeler. Proc Natl Acad Sci U S A (2009) 3.02

PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. EMBO J (2009) 2.99

Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse. EMBO J (2003) 2.94

PARP-2, A novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase. J Biol Chem (1999) 2.92

Telosome, a mammalian telomere-associated complex formed by multiple telomeric proteins. J Biol Chem (2004) 2.76

Resistance to endotoxic shock as a consequence of defective NF-kappaB activation in poly (ADP-ribose) polymerase-1 deficient mice. EMBO J (1999) 2.75

Spatial and temporal cellular responses to single-strand breaks in human cells. Mol Cell Biol (2003) 2.70

In situ analysis of repair processes for oxidative DNA damage in mammalian cells. Proc Natl Acad Sci U S A (2004) 2.59

A nuclear poly(ADP-ribose)-dependent signalosome confers DNA damage-induced IkappaB kinase activation. Mol Cell (2009) 2.56

Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res (2008) 2.56

Poly(ADP-ribosyl)ation of polynucleosomes causes relaxation of chromatin structure. Proc Natl Acad Sci U S A (1982) 2.37

The second zinc-finger domain of poly(ADP-ribose) polymerase determines specificity for single-stranded breaks in DNA. Proc Natl Acad Sci U S A (1990) 2.32

Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem Biophys Res Commun (1963) 2.26

DNA repair defect in poly(ADP-ribose) polymerase-deficient cell lines. Nucleic Acids Res (1998) 2.21

Feedback-regulated poly(ADP-ribosyl)ation by PARP-1 is required for rapid response to DNA damage in living cells. Nucleic Acids Res (2007) 2.08

Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination. Nat Struct Mol Biol (2010) 2.07

A role of poly (ADP-ribose) polymerase in NF-kappaB transcriptional activation. Biol Chem (1999) 2.06

PARP-1 regulates chromatin structure and transcription through a KDM5B-dependent pathway. Mol Cell (2010) 2.06

DNA methylation and the regulation of gene transcription. Cell Mol Life Sci (2002) 2.02

FACT-mediated exchange of histone variant H2AX regulated by phosphorylation of H2AX and ADP-ribosylation of Spt16. Mol Cell (2008) 1.99

DNA-damage repair; the good, the bad, and the ugly. EMBO J (2008) 1.89

Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic. J Med Chem (2010) 1.86

PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer Res (2010) 1.84

Identification and characterization of a mammalian 39-kDa poly(ADP-ribose) glycohydrolase. J Biol Chem (2005) 1.83

Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis. Breast Cancer Res Treat (2010) 1.81

The DNA damage response pathways: at the crossroad of protein modifications. Cell Res (2008) 1.80

A cytoplasmic ATM-TRAF6-cIAP1 module links nuclear DNA damage signaling to ubiquitin-mediated NF-κB activation. Mol Cell (2010) 1.79

Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst (2010) 1.74

A third zinc-binding domain of human poly(ADP-ribose) polymerase-1 coordinates DNA-dependent enzyme activation. J Biol Chem (2007) 1.72

Polymorphisms in DNA base excision repair genes ADPRT and XRCC1 and risk of lung cancer. Cancer Res (2005) 1.69

Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. J Med Chem (2009) 1.68

ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors. Mol Cancer Ther (2010) 1.67

Human poly(ADP-ribose) glycohydrolase is expressed in alternative splice variants yielding isoforms that localize to different cell compartments. Exp Cell Res (2004) 1.66

PARP1 ADP-ribosylates lysine residues of the core histone tails. Nucleic Acids Res (2010) 1.64

PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med (2010) 1.64

Identification of genetic variants in base excision repair pathway and their associations with risk of esophageal squamous cell carcinoma. Cancer Res (2004) 1.64

Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells. Cancer Res (2010) 1.64

In silico characterization of the family of PARP-like poly(ADP-ribosyl)transferases (pARTs). BMC Genomics (2005) 1.62

CCCTC-binding factor activates PARP-1 affecting DNA methylation machinery. J Biol Chem (2008) 1.62

To cell cycle, swing the APC/C. Biochim Biophys Acta (2008) 1.60

PARP-1, PARP-2 and ATM in the DNA damage response: functional synergy in mouse development. DNA Repair (Amst) (2004) 1.58

Genetic interaction between PARP and DNA-PK in V(D)J recombination and tumorigenesis. Nat Genet (1997) 1.52

Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types. Genes Cancer (2010) 1.48

The Zn3 domain of human poly(ADP-ribose) polymerase-1 (PARP-1) functions in both DNA-dependent poly(ADP-ribose) synthesis activity and chromatin compaction. J Biol Chem (2010) 1.47

Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. Proc Natl Acad Sci U S A (2010) 1.47

The effect of poly(ADP-ribosyl)ation on native and H1-depleted chromatin. A role of poly(ADP-ribosyl)ation on core nucleosome structure. J Biol Chem (1989) 1.46

DNA methylation and chromatin structure: the puzzling CpG islands. J Cell Biochem (2005) 1.45

The kinetochore and the centromere: a working long distance relationship. Annu Rev Genet (2009) 1.44

Parp1 facilitates alternative NHEJ, whereas Parp2 suppresses IgH/c-myc translocations during immunoglobulin class switch recombination. J Exp Med (2009) 1.44

The ADPRT V762A genetic variant contributes to prostate cancer susceptibility and deficient enzyme function. Cancer Res (2004) 1.41

Toward specific functions of poly(ADP-ribose) polymerase-2. Trends Mol Med (2008) 1.39

Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect. J Clin Invest (2007) 1.39

Histone shuttling by poly(ADP-ribosylation). J Biol Chem (1992) 1.38

ADP-ribosylation of histone H1. Identification of glutamic acid residues 2, 14, and the COOH-terminal lysine residue as modification sites. J Biol Chem (1980) 1.38

The alternative end-joining pathway for repair of DNA double-strand breaks requires PARP1 but is not dependent upon microhomologies. Nucleic Acids Res (2010) 1.37

Telomeres in cancer and ageing. Philos Trans R Soc Lond B Biol Sci (2011) 1.36

ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. Clin Cancer Res (2009) 1.36

Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem (2009) 1.35

Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer. Cancer (2010) 1.35

Global analysis of transcriptional regulation by poly(ADP-ribose) polymerase-1 and poly(ADP-ribose) glycohydrolase in MCF-7 human breast cancer cells. J Biol Chem (2009) 1.32

6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance. Cancer Res (2010) 1.29

Null mutation of DNA strand break-binding molecule poly(ADP-ribose) polymerase causes medulloblastomas in p53(-/-) mice. Am J Pathol (2003) 1.28

Centromere proteins Cenpa, Cenpb, and Bub3 interact with poly(ADP-ribose) polymerase-1 protein and are poly(ADP-ribosyl)ated. J Biol Chem (2002) 1.27

Functional interaction between poly(ADP-Ribose) polymerase 2 (PARP-2) and TRF2: PARP activity negatively regulates TRF2. Mol Cell Biol (2004) 1.27

Mitochondrial cholesterol loading exacerbates amyloid beta peptide-induced inflammation and neurotoxicity. J Neurosci (2009) 1.27

Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma. Cancer Res (2008) 1.21

The cyclin-dependent kinase inhibitor, p21(WAF1), promotes angiogenesis by repressing gene transcription of thioredoxin-binding protein 2 in cancer cells. Carcinogenesis (2009) 0.89

Probiotic sonicates selectively induce mucosal immune cells apoptosis through ceramide generation via neutral sphingomyelinase. PLoS One (2011) 0.86

GD3 synthase overexpression sensitizes hepatocarcinoma cells to hypoxia and reduces tumor growth by suppressing the cSrc/NF-kappaB survival pathway. PLoS One (2009) 0.83

Design, synthesis, crystallographic studies, and preliminary biological appraisal of new substituted triazolo[4,3-b]pyridazin-8-amine derivatives as tankyrase inhibitors. J Med Chem (2014) 0.80

Parp-2 is required to maintain hematopoiesis following sublethal γ-irradiation in mice. Blood (2013) 0.77

[Spanish multi-centre observational study of the first attacks suggestive of multiple sclerosis: the PREM cohort]. Rev Neurol (2011) 0.75